Long Term Outcome of Patients with Acute Myelogenous Leukemia: The Role of Maintenance Therapy, Consolidation Therapy and the Predictive Value of Twoin vitroAssays
作者:
RazaA.,
PreislerH. D.,
BrowmanG. P.,
LarsonR. A.,
RustumY. M.,
GoldbergJ.,
VoglerR.,
MillerK. A.,
BennettJ.,
KuklaC.,
期刊:
Leukemia&Lymphoma
(Taylor Available online 1993)
卷期:
Volume 10,
issue 1-2
页码: 57-66
ISSN:1042-8194
年代: 1993
DOI:10.3109/10428199309147357
出版商: Taylor&Francis
关键词: Cytosine arabinoside triphosphate;acute tnyeloid leukemia;clonogenicity;remission induction therapy;remission duration
数据来源: Taylor
摘要:
Three successive strategies used to treat acute myelogenous leukemia (AML) patients who entered complete remission are compared with respect to their long term efficacy (>5 years). Additionally, the ability of twoin vitroassays to identify patients who would be long term remitters was assessed. With respect to the proportion of patients in long term remission, 5 years of maintenance therapy, intensive consolidation therapy plus 3 years of additional therapy, and 4 courses of consolidation therapy produced equivalent results with 18 to 22% of patients in remission at 7 years. Patients whose leukemia cells retained high levels of cytosine arabinoside triphosphate (araCTP) and who received maintenance therapy were less likely to experience early relapse than comparably treated patients whose leukemia cells failed to retain araCTP. The failure of leukemia cells to clonein vitrowas also associated with a lower early relapse rate for patients who received maintenance therapy. Neither the ability of leukemia cells to retain araCTP nor their ability to clone in vitro were of prognostic significance for patients treated with 4 courses of intensive consolidation therapy.
点击下载:
PDF (643KB)
返 回